Gene regulation network analysis reveals core genes associated with survival in glioblastoma multiforme

Abstract

Glioblastoma multiforme (GBM) is a very serious mortality of central nervous system cancer. The microarray data from http://GSE2223, http://GSE4058, http://GSE4290, http://GSE13276, http://GSE68848 and http://GSE70231 (389 GBM tumour and 67 normal tissues) and the RNA‐seq data from TCGA‐GBM dataset (169 GBM and five normal samples) were chosen to find differentially expressed genes (DEGs). RRA (Robust rank aggregation) method was used to integrate seven datasets and calculate 133 DEGs (82 up‐regulated and 51 down‐regulated genes). Subsequently, through the PPI (protein‐protein interaction) network and MCODE/ cytoHubba methods, we finally filtered out ten hub genes, including FOXM1, CDK4, TOP2A, RRM2, MYBL2, MCM2, CDC20, CCNB2, MYC and EZH2, from the whole network. Functional enrichment analyses of DEGs were conducted to show that these hub genes were enriched in various cancer‐related functions and pathways significantly. We also selected CCNB2, CDC20 and MYBL2 as core biomarkers, and further validated them in CGGA, HPA and CCLE database, suggesting that these three core hub genes may be involved in the origin of GBM. All these potential biomarkers for GBM might be helpful for illustrating the important role of molecular mechanisms of tumorigenesis in the diagnosis, prognosis and targeted therapy of GBM cancer.

Bioinformatics Analysis Discovers Microtubular Tubulin Beta 6 Class V (TUBB6) as a Potential Therapeutic Target in Glioblastoma

“…The discovery of potential biomarkers is important to improve diagnosis, prognosis, and targeted therapy of GBM. Recently, we detected the HMG-box family establishing the significance of SOX6 in the malignant progression of GBM (Jiang et al, 2020a), and found three core genes associated with survival in GBM (Jiang et al, 2020b). Besides, another study revealed that expression of 77 known genes can serve as biomarker in pan-cancer (Ji and Cui, 2020).…”

Identification of prognostic biomarkers for suppressing tumorigenesis and metastasis of Hepatocellular carcinoma through transcriptome analysis

“…In this study, amplification was found as genetic alterations in 0.57% of the patients. In GBM, CCNB2 acted as potential biomarker and played a vital role in Cellular Senescence and cell cycle (Jiang et al, 2020). These have missense mutation at location P80S having phosphorylation PTM site and amplification in 0.57% of the patients and shallow deletion copy number alterations.…”

NPC2 as a Prognostic Biomarker for Glioblastoma Based on Integrated Bioinformatics Analysis and Cytological Experiments

“…Accurate and effective prognosis assessment play an important role in individualized treatment and follow-up treatment of patients with GBM. GBM is usually diagnosed in the late stage by MRI with poor prognosis, therefore, a reliable prognostic marker is essential ( Jiang et al, 2020 ). Indeed, effective prognostic care for GBM patients requires a better understanding of the molecular mechanism of GBM.…”